Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, cofounder Patrick Hsu, Ph.D., told Fierce Biotech. | Stylus Medicine is ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...

The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered ...

Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline ...

North Carolina-based CRO Fortrea is saying goodbye to its CEO. | North Carolina-based CRO Fortrea is saying goodbye to its ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

The FDA has cleared its first at-home collection kit that allows women to screen themselves for human papillomavirus and ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...